Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31547777 | 0.98 | KDM4E (0.52) | KDM4ECYP3A4GAAPDPK1CYP1A2 | |
| Hydrochloric Acid SCHEMBL892688 | 0.98 | KDM4E (0.52) | KDM4ECYP3A4GAAPDPK1CYP1A2 | |
| SCHEMBL2071550 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4GAAPDPK1CYP1A2 | |
| SCHEMBL702375 | 0.84 | PRMT5 (0.61) | KDM4ECYP3A4GAAPDPK1CYP1A2 | |
| SCHEMBL31530816 | 0.81 | KDM4E (0.48) | KDM4ECYP3A4GAAPDPK1CYP1A2 | |
| SCHEMBL730150 | 0.81 | KDM4E (0.48) | KDM4ECYP3A4GAAPDPK1CYP1A2 | |
| SCHEMBL7714118 | 0.81 | KDM4E (0.48) | KDM4ECYP3A4GAAPDPK1CYP1A2 | |
| SCHEMBL3347649 | 0.81 | KDM4E (0.48) | KDM4ECYP3A4GAAPDPK1CYP1A2 | |
| SCHEMBL6450219 | 0.81 | KDM4E (0.48) | KDM4ECYP3A4GAAPDPK1CYP1A2 | |
| SCHEMBL1326632 | 0.78 | KDM4E (0.46) | KDM4ECYP3A4GAAPDPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672582-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4680236-A2 | 3-ALKYLAMINE INDOLE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| US-12421185-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2024192150-A2 | 3-ALKYLAMINE INDOLE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-11529338-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529338-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2021-06-03 | — | — | US | disclosed |
| US-10927070-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2021-02-23 | — | — | US | disclosed |
| US-20030230363-A1 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON | 2003-12-18 | — | — | US | disclosed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | disclosed |
| WO-2003066029-A2 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-1178045-B1 | Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents | PFIZER (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-0870768-B1 | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1178045-A1 | Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents | PFIZER INC. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5977131-A | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0870768-A1 | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | KDM4E 3204/4885CYP3A4 306/4885GAA 296/4885 |
| US-12421185-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | KDM4E 2650/4885CYP3A4 4846/4885GAA 703/4885 |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TSG101, RNASE1, TP53 | KDM4E 2650/4885CYP3A4 4846/4885GAA 703/4885 |
| US-11529338-B2 | Compositions and methods for treating cancer | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | KDM4E 3951/4885CYP3A4 4880/4885GAA 900/4885 |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | GLI1, RCC2, BRCA1 | KDM4E 1875/4885CYP3A4 4173/4885GAA 4271/4885 |
| US-10927070-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | KDM4E 2650/4885CYP3A4 4846/4885GAA 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.